KDM1A and glioblastoma: Our evaluation of pharmacological LSD1 inhibition in a diverse panel of GSC models suggests the need for future investigations of brain penetrant LSD1 inhibitors alone, or in combination with other therapeutic approaches to synergize efficacy for GBM.